Myra Vision Launches Pioneering Clinical Study for Glaucoma
Myra Vision is at the forefront of innovation in glaucoma treatment with its new clinical initiative. The company recently announced that the first patient has been treated in its ADAPT clinical study, a significant milestone in the quest to improve outcomes for patients suffering from glaucoma.
Introduction to the Calibreye™ TGT Surgical System
The Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System is designed to optimize intraocular pressure (IOP) management effectively. This surgical system is unique as it allows for customizable IOP adjustments post-surgery, tailoring the treatment to meet each patient's specific needs. This capability is particularly revolutionary in managing glaucoma, a condition that remains one of the leading causes of irreversible blindness globally.
First Patient Enrolment and Study Details
The initial treatment was performed by Dr. David Godfrey, who is associated with Glaucoma Associates of Texas. The ADAPT study will include up to 70 refractory glaucoma patients and will assess the safety and efficacy of the Calibreye system over a primary effectiveness endpoint spanning 12 months. Through this study, Myra Vision aims to collect comprehensive data that may demonstrate the device's capability in real-world clinical settings.
Significance of the ADAPT Study
For many patients with glaucoma, traditional surgical options do not provide the necessary flexibility in managing their condition. The design of the Calibreye system is intended to bridge this gap by allowing clinicians to fine-tune IOP levels as needed, thereby potentially reducing complications associated with fixed surgical implants.
Clinical Insights from Experts
Dr. Ike Ahmed, an esteemed advisor to Myra Vision and Director at the Alan S. Crandall Center for Glaucoma Innovation, expressed his enthusiasm, stating that after years of development, witnessing the trial's initiation is incredibly gratifying. He highlighted the device's potential to significantly benefit patients who face severe glaucoma challenges.
Patient Impact and Future Directions
Glaucoma affects millions, and its progression can result in debilitating vision loss. The Calibreye system's innovative approach aims to provide patients and healthcare providers with a proactive tool for IOP management. Historically, patients have depended on limited surgical solutions that may not adapt to evolving medical needs.
What to Expect from Myra Vision
Robert Chang, the President and CEO of Myra Vision, reflected on this accomplishment, emphasizing the vital nature of personalized medical care. The Calibreye could enable doctors to offer tailored treatment plans, enhancing patient outcomes in an area of medicine that has not seen significant advancements in recent years.
Conclusion and Company Overview
The Calibreye system is currently designated for investigational purposes exclusively and is not available for commercial sale in the United States or internationally. Myra Vision, founded as a privately held entity within the Shifamed portfolio, is committed to pioneering advancements in medical technology. The company focuses on developing innovative solutions that prioritize patient context and optimize care delivery methods.
About Myra Vision, Inc.
Myra Vision is developing a novel aqueous shunt that emphasizes safe, effective IOP control specifically designed to meet individual patient requirements while minimizing complexity. This commitment underlines their mission to innovate healthcare solutions.
About Shifamed, LLC.
Shifamed, LLC is a unique hub centered on medical innovation. Founded by Amr Salahieh, the organization aims to bring medical solutions to market swiftly, effectively, and responsibly, ensuring patients live healthier lives.
Frequently Asked Questions
What is the ADAPT clinical study?
The ADAPT clinical study is a trial to evaluate the safety and effectiveness of the Calibreye™ TGT Surgical System for patients with glaucoma.
Who performed the first patient treatment?
The first treatment was conducted by Dr. David Godfrey at Glaucoma Associates of Texas.
What are the benefits of the Calibreye system?
The Calibreye system allows for customizable IOP adjustments, potentially improving treatment outcomes for glaucoma patients.
How many patients will be enrolled in the ADAPT study?
Up to 70 refractory glaucoma patients will be enrolled in the ADAPT clinical study.
Is the Calibreye system available for sale?
No, the Calibreye system is currently for investigational use only and is not for sale in the U.S. or outside the U.S.
